Combining the mTORC1/2 inhibitor #onatasertib with the #PD1antibody #toripalimab offers a manageable safety profile and promising efficacy in advanced #SolidTumors—especially recurrent or #MetastaticCervicalCancer—regardless of #PDL1 expression.

#STTT: doi.org/10.1038/s413...

A multicenter, nonrandomized phase 1/2 trial on #onatasertib in combination with #toripalimab in patients with advanced solid tumors demonstrated a manageable safety profile and encouraging antitumor activity. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...